The association of adiposity with survival and immunologic toxicity in cancer patients treated with anti-PD-1/PD-L1 agents remains extremely complex also due to some conflicting results, negative reports and, above all, to a still inadequate understanding of its clinico-pathologic and immunologic determinants [2, 3, 14, 16, 21, 24, 25]. The gene discussed is PDCD1; the disease is cancer.